Antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation
View Patent ↗The present application relates to an antigen peptide derived from the sequence of epidermal growth factor receptor having T790M point mutation and a pharmaceutical composition for the treatment of cancer comprising the peptide.
1. A method of treating cancer by inducing peptide-specific cytotoxic T lymphocytes (CTLs), comprising administering a peptide consisting of the amino acid sequence of SEQ ID NO: 5, 7 or 15 to a patient in need thereof.
2. The method according to claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 5.
3. The method according to claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 7.
4. The method according to claim 1 , wherein the peptide consists of the amino acid sequence of SEQ ID NO: 15.
5. The method according to claim 1 , wherein the peptide is administered intradermally or subcutaneously.
6. The method according to claim 1 , wherein the peptide is administered with an incomplete Freund's adjuvant, a polysaccharide, or an immunopotentiating agent.
7. The method according to claim 1 , wherein the peptide is administered with incomplete Freund's adjuvant ISA-51, pullulan, complete Freund's adjuvant, Bacillus Calmette-Guérin (BCG), Alum, Granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), or CpG.
8. The method according to claim 1 , wherein from 0.0001 mg to 1000 mg of the peptide is administered.
9. The method according to claim 1 , wherein the peptide is administered in a liposome.
10. The method according to claim 1 , wherein the peptide is bound to a lipid.